These results suggest that the combination of HLA-B*15:01 and DRB1*15:01 is associated with ILD in Japanese patients with advanced pancreatic cancer receiving gemcitabine plus erlotinib. This evidence concerns the gene HLA-B and familial pancreatic carcinoma.